Immuno-stimulatory monoclonal antibodies

• US 5,897,862 A
• Filed: 01/30/1995
• Issued: 04/27/1999
• Est. Priority Date: 01/31/1994
• Status: Expired due to Term

• Current Assignee: Mor Research Applications Ltd. (Clalit Health Services)
• Original Assignee: Mor Research Applications Ltd. (Clalit Health Services)
• Inventors: Novogrodsky, Avraham, Hardy, Britta
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): Johnson, Nancy A.
• Application Number:
  US08/380,857
• Time in Patent Office: 1,548 Days
• Field of Search: 530/387.14, 530/388.2, 530/388.7, 530/388.73, 435/240.27, 435/332, 435/343.1, 424/152.1, 424/153.1
• US Class Current: 424/153.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants

Abstract

A monoclonal antibody having immuno-stimulatory effects, binds specifically to B lymphoblastoid cells and induces proliferation and activation of peripheral blood lymphocytes, and when injected into tumor-bearing animals elicts an anti-tumor effect.

Claims

1. A monoclonal antibody or an antigen binding fragment thereof, wherein the monoclonal antibody

i. is secreted by the hybridoma cell line deposited at the Collection Nationale de Cultures de Microorganismes (CNCM), under Accession No. I-1397, or

ii. recognizes the same antigenic epitope as the antibody under (i).

2. A monoclonal antibody or antigen binding fragment according to claim 1, secreted by the hybridoma cell line deposited at CNCM under Accession No. I-1397.

3. An immortalized cell line secreting an antibody according to claim 1.

4. An immortalized cell line according to claim 3, which is a hybridoma cell line.

5. A hybridoma cell line according to claim 4, wherein the hybridoma cell line is deposited at the CNCM under Accession No. I-1397.

6. A method for the treatment of cancer in an individual comprising administering to said individual a therapeutically effective amount of a monoclonal antibody according to claim 1 so as to elicit an anti-tumor effect in the treated individual.

7. A method according to claim 6, wherein the monoclonal antibody is that secreted by the hybridoma cell line deposited at the CNCM under Accession No. I-1397.

8. A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of a monoclonal antibody according to claim 1 so as to elicit an anti-tumor effect in the treated individual, and a physiologically acceptable carrier.

9. A pharmaceutical composition according to claim 8, wherein the antibody is that secreted by the hybridoma cell line deposited at the CNCM under Accession No. I-1397.